BioArctic partner Eisai wins FDA approval for Leqembi Iqlik subcutaneous starting dose

  • FDA cleared once-weekly Leqembi Iqlik subcutaneous injection as a starting dose for early Alzheimer’s disease, expanding lecanemab beyond IV initiation.
  • Eisai plans a U.S. launch in late August 2026; regimen starts at 500 mg weekly via autoinjector.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioArctic AB published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607132242PR_NEWS_EURO_ND__EN03698) on July 14, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.